COMMUNIQUÉS West-GlobeNewswire

Accumulus Synergy crée Accumulus Technologies pour développer sa plateforme réglementaire éprouvée et accélérer l’accès mondial aux thérapies
07/08/2025
BURLINGAME, Californie, 07 août 2025 (GLOBE NEWSWIRE) -- Dans une démarche audacieuse visant à accélérer l’innovation réglementaire et à répondre à la demande mondiale croissante, Accumulus Synergy, une association [...]
IBA Notice of Half Year 2025 Results and Conference Call
07/08/2025
HY25 results webcast to take place on Thursday, 28 August 2025 at 3pm CEST Louvain-la-Neuve, Belgium, 07 August 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, [...]
IBA : Publication des résultats du premier semestre 2025 et conférence web
07/08/2025
La conférence sur les résultats des six premiers mois de 2025 aura lieu le jeudi 28 août 2025 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 7 août 2025 - IBA (Ion Beam Applications S.A le leader mondial des [...]
SNIPR BIOME Raises EUR 35 Million Series B Financing to Advance CRISPR-Medicines Targeting Antimicrobial Resistance
07/08/2025
COPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with [...]
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
07/08/2025
Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ ® in individuals [...]
Valneva annonce la levée de l’arrêt temporaire de la FDA sur l’utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes âgées et une mise à jour des caractéristiques du produit
07/08/2025
Saint Herblain (France), le 7 août 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui la levée de l’arrêt temporaire de l’agence de santé américaine Food [...]
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
07/08/2025
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, today presents its [...]
Sana Biotechnology Announces Pricing of Public Offering
07/08/2025
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its [...]
CORRECTING and REPLACING - Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update
07/08/2025
In a release issued under the same headline on August 6, 2025 by Inotiv, Inc. (NASDAQ: NOTV), please note that the amount of the recent draw request on the revolving credit facility has been corrected. The corrected [...]
Extendicare Announces 2025 Second Quarter Results
06/08/2025
MARKHAM, Ontario, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and six months ended June 30, 2025. Second Quarter 2025 Highlights [...]
Cannabis: The Gateway to Tomatoes? New Survey Says Yes
06/08/2025
Homegrown Cannabis Co. study reveals most cannabis growers eventually become home vegetable gardeners FORT LAUDERDALE, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cannabis isn’t just transforming laws and lifestyles but [...]
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/08/2025
MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
06/08/2025
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an [...]
STERIS Announces Chief Financial Officer Transition
06/08/2025
Long-time CFO Michael J. Tokich to be succeeded by Karen L. Burton, Chief Accounting Officer DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that [...]
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
06/08/2025
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of proprietary oral small [...]
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
06/08/2025
Safety Review Committee endorses escalation to 160 mg TUS dosing Cohorts with 120 mg, 80 mg, 40 mg TUS dosing completed with no dose-limiting toxicities Excellent safety and complete remissions (CRs) in some of the most [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
06/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt [...]
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
06/08/2025
Enrollment Complete in Cohorts 1 and 2 of MyPEAK™ -1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN- [...]
STERIS Announces Financial Results for Fiscal 2026 First Quarter
06/08/2025
Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79; adjusted EPS increased to $2.34 Fiscal 2026 revenue and [...]

Pages